The postdoc project involves the implementation of a CRISPR/Cas9 screening approach to dissect the molecular composition of a recently identified novel pathway of programmed cell death induced during infection with the obligate intracellular bacterial pathogen Chlamydia trachomatis.

The full-time scholarship is for 1+1 years (with possibility for further prolongation depending on satisfactory performance). Starting date: as soon as a suitable candidate can be found.

Qualifications:
The ideal candidate should have a PhD in molecular biology, cell biology, or microbiology (or equivalent). Thorough theoretical and practical knowledge in molecular and cell biology is a prerequisite. Knowledge within the field of infection biology and/or programmed cell death is considered an advantage. Moreover, candidates with bioinformatics skills, in particular experience in handling and analyzing data from next-generation sequencing projects, will be preferred. The ideal candidate should be passionate about science and be willing to take on scientific and technical challenges. The candidate should be proficient in written and spoken English and is expected to work both independently and as part of an interactive team.

Application:
To apply for the fellowship, the applicant should prepare a single PDF (max 5 pages) containing: 1) a letter of motivation describing the applicant’s interest in the project and how the applicant’s previous experience and skills can contribute to the project, 2) a curriculum vitae including a description of the methods that the applicant has mastered, and 3) names and e-mail addresses for two or more references, with stated professional relationship to the applicant. Applications should be written in English.

The application PDF should be sent to barbara.sixt@umu.se. Applications are possible from now until a suitable candidate was found.

More information about Barbara Sixt’s lab:
http://www.mims.umu.se/groups/barbara-sixt.html
https://projects.au.dk/nordic-embl-partnership/show-news/artikel/introducing-mims-embl-group-leaders-barbara-sixt-cell-autonomous-immunity/